Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial.

Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Actinium-225 offers a different approach by using alpha particles instead of beta particles. Alpha particles are highly energetic and travel only a short distance, which allows them to effectively ...

When Marie Curie died in 1934, the discoverer of actinium, André-Louis Debierne ... method of chemical analysis’ in a sample of the minerals lepidolite and pollucite, naming their discovery ...

Actinium is a clinical-stage biopharmaceutical company that has devised an innovative strategy to overcome these hurdles. The company is leveraging its Antibody Warhead Enabling (AWE) technology ...

Actinium Pharmaceuticals Stock Down 4.9 % Shares of ATNM opened at $1.17 on Friday. The stock has a market capitalization of $36.50 million, a P/E ratio of -0.84 and a beta of 0.13. The firm has a ...

Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...

At the forefront of this development is Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing ARCs. It uses use internal radiation to fight cancer, by linking a ...